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Selective estrogen receptor modulators in chronic renal failure. (BMD) and higher bone resorption markers, compared
Background. In addition to renal osteodystrophy, post- to similar women with normal menstruation [2]. At the
menopausal women on dialysis could be at risk of osteoporosis. same time, only a few postmenopausal uremic womenHormone replacement therapy (HRT) could have beneficial
are being offered hormone replacement therapy (HRT),effects as well as potentially serious risks, especially in uremic
indicating that these patients are managed differentlywomen, due to the pharmacokinetics of estradiol in renal fail-
ure. Therapeutic alternatives, such as the selective estrogen than nonuremic women. Apart from the lack of aware-
receptor modulators (SERMs), have shown the benefits of ness of the treating physicians, women with end-stage
estrogen on bone and serum lipid levels, without its adverse renal failure are usually stoic and rarely complain abouteffects on the breast and endometrium, in nonuremic women.
gynecologic problems that may seem trivial in compari-Methods. Recent data on the effect of the SERM raloxifene
son to their renal disease burden [3–6].in bone and lipid metabolism in osteoporotic postmenopausal
women on dialysis is reviewed. Since the estrogen receptor The adverse effects of hypoestrogenism on bone have
(ER) gene has been suggested as a candidate marker for osteo- been widely recognized. Lack of estrogens is associated
porosis, we investigated whether ER polymorphism could have
with increased osteoclastic bone resorption [7–10]. Inpredicted the BMD response to raloxifene.
addition, estrogen may affect parathyroid hormone ac-Results. Hemodialyzed women on raloxifene demonstrated
increased trabecular bone mineral density (BMD) and de- tion by increasing PTH mRNA at the parathyroid gland
creased bone resorption markers. Similarly, LDL-cholesterol [11] and modulating PTH action on bone. Clinical evi-
values dropped significantly. ER gene polymorphism analysis dence in favor of an effect of estrogen in uremic bone
of baseline BMD parameters did not differ between PP/xx or
disease has been recently suggested in a controlled studyPp/Xx groups. Nevertheless, patients on raloxifene with PP/xx
of a small group of postmenopausal women on dialysis,genotypes, but not those with Pp/Xx, showed a higher trabecu-
lar BMD after one year on treatment, suggesting that homozy- in which treatment with transdermal estradiol and the
gous women for P or x alleles of the ER have a better BMD cyclic addition of norestisterone acetate significantly in-
response to raloxifene. creased lumbar spine BMD after one year [12].
Conclusion. Raloxifene and, most likely, other SERMs,
Nevertheless, there could be some problems with thecould represent a good alternative to HRT in postmenopausal
use of HRT in uremic women. First, it has been demon-uremic women.
strated that women on dialysis, when compared to non-
uremic women, showed elevated baseline estradiol levels
which increased significantly after the ingestion of estra-
diol. This could suggest that renal failure may decrease
ESTROGEN AND BONE IN UREMIA estradiol catabolism and affect the pharmacokinetics of
The term osteoporosis must be applied with caution exogenous estradiol [13]. Second, a recent study on the
in both uremic and patients on dialysis, who have a risks and benefits of estrogen plus progestin in healthy
complex range of metabolic bone disease [1]. Neverthe- postmenopausal women has introduced a word of cau-
less, osteoporosis could begin early in time. An impor- tion in HRT therapy [14]. In this randomized controlled
tant proportion of young women on dialysis (50 years primary prevention trial of the Women’s Health Initia-
old) are already amenorrheic and relatively hypoestro- tive, in which 16,608 postmenopausal women were fol-
genic with significantly lower bone mineral density lowed for 5.2 years, it was demonstrated that the out-
comes were more harmful than beneficial in the estrogen
plus progestin group versus the placebo group. AlthoughKey words: osteoporosis, bone mineral density, hemodialysis, meno-
the estrogen plus progestin treatment reduced the ob-pause, hormone replacement therapy, selective estrogen receptor mod-
ulator, raloxifene. served hip and vertebral fracture rate and colon cancer
by one third, the rate of women experiencing coronary 2003 by the International Society of Nephrology
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heart disease increased by 29%, venous thromboembo-
lism was twofold greater, stroke rates were increased by
41%, and invasive breast cancer increased by 26%.
SELECTIVE ESTROGEN RECEPTOR
MODULATORS IN HEALTHY WOMEN
Several alternatives are available for women who can-
not, or refuse to, take estrogen. Two potential estrogen-
like therapies include raloxifene and tamoxifen. These
are selective estrogen receptor modulators (SERMs),
and they possess tissue-selective estrogen agonist and
antagonist properties [15]. In ovariectomized animals,
raloxifene preserves bone density, lowers serum total
Fig. 1. Changes in lumbar spine BMD (g/cm2) in postmenopausal hem-
cholesterol concentrations, and inhibits aortic choles- odialyzed women given raloxifene 60 mg/day or placebo for one year.
Open bars represent values at baseline and the closed bars after oneterol accumulation, without causing endometrial hyper-
year of treatment. *P  0.01.plasia [16]. The mechanism responsible for the apparent
tissue-selective activity of raloxifene is not completely
understood. In vitro experiments suggest that raloxifene
has different effects than estradiol at the estrogen recep- Baseline blood determinations and BMD analysis
tor, including differential modulation of DNA response were obtained. Blood was drawn every three months,
elements [17] and induction of a different conformational and BMD was evaluated after one year. To investigate
change in the transactivation domain of the ligand-bind- whether the ER polymorphism could have predicted the
response of BMD to raloxifene in those postmenopausaling domain [18]. A long-term (40 months) clinical trial,
women in chronic hemodialysis, blood was obtained forthe Multiple Outcomes of Raloxifene Evaluation (MORE)
genomic DNA extraction from peripheral leukocytes.study, involving 7705 postmenopausal women with os-
The ER gene polymorphic region for both PvuII andteoporosis, found that raloxifene’s antagonistic effect on
XbaI, located in part of intron 1 and exon 2, was ampli-the breast appeared to cause a reduction in the risk of
fied by PCR using the following primers:breast cancer [19]. Raloxifene did not increase the risk
of endometrial cancer, but there was an increased inci-
5 – CTG CCA CCC TAT CTG TAT CTT TTC CTAdence of thromboembolic disease, hot flashes, influenza-
TTC TCC – 3like symptoms, peripheral edema, and leg cramps. In
5 – TCT TTC TCT GCC ACC CTG GCG TCG ATTthis same study, most of the women had lumbar spine
ATC TGA – 3x-rays at baseline and after 36 months of treatment.
Among the women receiving 60 mg raloxifene, 6.6% had
After digestion, the products of PvuII and XbaI re-new vertebral fractures, compared with 10.1% in the
striction fragment length polymorphism (RFLP) were
placebo group, but the risk of nonvertebral fractures was
submitted to agarose gel electrophoresis. The presence
similar. Thus, treatment of uremic women with a SERM, of the restriction site was labeled as p or x alleles (for
with their spectrum of breast and uterus antagonist ef- PvuII and XbaI reactions, respectively), and its absence
fects, and action on bone as an estrogen agonist, seems as P or X.
a less harmful and more rational therapeutic strategy [20]. Both groups of women were similar regarding age,
time on dialysis, time after menopause, medical manage-
ment of renal osteodystrophy, and degree of osteoporo-
SELECTIVE ESTROGEN RECEPTOR
sis or osteopenia. Blood biochemical parameters, includ-
MODULATORS IN UREMIC WOMEN ing serum creatinine, calcium, PTH, and phosphorus, as
We have recently analyzed results from a prospective, well as sexual hormone levels (total estradiol, follicle
controlled, double-blind study on the effect of raloxifene stimulating hormone, and luteinizing hormone) were
on bone and lipid metabolism on postmenopausal also similar in both groups.
women on hemodialysis with severe osteopenia (Her- Bone mineral density at the lumbar spine improved
na´ndez E et al, in press). Selected women were more significantly after one year of treatment with raloxifene,
than 50 years old, had at least two years of menopause, with no change in the placebo group (Fig. 1). No signifi-
and evidence of severe osteopenia or osteoporosis (T cant changes were observed at the femoral neck. Like-
wise, there was a decrease in markers of bone resorptionscore below 2.0 SD).
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in high-risk women with respect to coronary and cerebro-
vascular events. The long-term effect of SERMs in
chronic renal failure patients remains to be determined.
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